Home / Healthcare / Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Pipeline Review, H1 2016

Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Pipeline Review, H1 2016

Published: Jun 2016 | No Of Pages: 58 | Published By: Global Markets Direct

Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Pipeline Review, H1 2016’, provides in depth analysis on Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1)
- The report reviews Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) Overview 7
Therapeutics Development 8
Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Products under Development by Stage of Development 8
Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Products under Development by Therapy Area 9
Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Products under Development by Indication 10
Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Products under Development by Companies 14
Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Products under Development by Universities/Institutes 17
Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Therapeutics Assessment 19
Assessment by Monotherapy/Combination Products 19
Assessment by Mechanism of Action 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Companies Involved in Therapeutics Development 25
CanBas Co., Ltd. 25
Cascadian Therapeutics Inc 26
Eli Lilly and Company 27
Genentech, Inc. 28
Sareum Holdings Plc 29
Vernalis Plc 30
Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Drug Profiles 31
CBP-501 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
CCT-244747 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
CCT-245737 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
FS-105 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
ONT-2409 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
prexasertib - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
RG-7741 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
SAR-020106 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Small Molecule to Inhibit Chk1 for Cancer - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Small Molecules to Inhibit Chk1 for Oncology - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
V-158411 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Dormant Projects 47
Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Discontinued Products 48
Serine/Threonine-Protein Kinase Chk1 (Checkpoint Kinase 1 or CHK1 Checkpoint Homolog or EC 2.7.11.1) - Featured News & Press Releases 49
May 23, 2016: Clinical Trials of CHK1 Inhibitor CCT245737 to Open at the Royal Marsden Hospital 49
Apr 19, 2016: Oncothyreon Highlights Novel Checkpoint Kinase 1 Inhibitors at American Association for Cancer Research (AACR) Annual Meeting 2016 49
Apr 05, 2016: CHK1 inhibitor CCT245737 Approved for Clinical Trials in Cancer Patients 50
Feb 01, 2016: CHK1 Clinical Trial Application Submissions 50
Dec 15, 2015: CHK1 Clinical Trial Applications 50
May 12, 2015: Sareum to Present at BioTrinity 2015 51
Apr 20, 2015: Lilly Releases Early-Stage Pipeline Data On LY2606368 at AACR Annual Meeting 2015 51
Apr 17, 2013: CanBas Announces Topline Results From Phase II Trial Of CBP501 In Patients With Non-Small Cell Lung Cancer 52
Jun 04, 2012: CanBas's CBP501 Meets Primary Endpoint In Phase II Study Of Malignant Pleural Mesothelioma 53
Jan 05, 2012: CanBas's CBP501 Receives Orphan Drug Designation From FDA For Malignant Mesothelioma 53
Nov 01, 2011: Canbas Enrolls Last Patient In Phase II Trial Of CBP501 As First-Line Treatment Of Malignant Pleural Mesothelioma 54
Oct 27, 2011: Canbas Announces Last Patient Enrolled In Phase II Trial Of CBP501 As First-Line Treatment Of Non-Small Cell Lung Cancer 54
Jan 20, 2010: New Molecules SAR-020106 Increase The Effectiveness Of Certain Cancer Therapies 55
Oct 06, 2009: Sareum And CRT Announce Results Of SAR-020106 At National Cancer Research Institute Cancer Conference 55
Jul 21, 2009: Vernalis Plc Announces New Oncology Development Candidate V158411 56
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 57
Disclaimer 58

Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Indication, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Early Stage Products, H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Development by Companies, H1 2016 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2016 17
Products under Investigation by Universities/Institutes, H1 2016 18
Assessment by Monotherapy/Combination Products, H1 2016 19
Number of Products by Stage and Mechanism of Action, H1 2016 20
Number of Products by Stage and Route of Administration, H1 2016 22
Number of Products by Stage and Molecule Type, H1 2016 24
Pipeline by CanBas Co., Ltd., H1 2016 25
Pipeline by Cascadian Therapeutics Inc, H1 2016 26
Pipeline by Eli Lilly and Company, H1 2016 27
Pipeline by Genentech, Inc., H1 2016 28
Pipeline by Sareum Holdings Plc, H1 2016 29
Pipeline by Vernalis Plc, H1 2016 30
Dormant Projects, H1 2016 47
Discontinued Products, H1 2016 48

Number of Products under Development for, H1 2016 8
Number of Products under Development by Top 10 Indication, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Monotherapy/Combination Products, H1 2016 19
Number of Products by Stage and Mechanism of Actions, H1 2016 20
Number of Products by Routes of Administration, H1 2016 21
Number of Products by Stage and Routes of Administration, H1 2016 21
Number of Products by Molecule Types, H1 2016 23
Number of Products by Stage and Molecule Type, H1 2016 23

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +